ViroGates A/S (CPH:VIRO)

Market Cap	106.28M +27.2%
Revenue (ttm)	8.90M +24.7%
Net Income	-10.40M
EPS	n/a
Shares Out	9.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259
Average Volume	867
Open	11.45
Previous Close	11.15
Day's Range	11.45 - 11.45
52-Week Range	5.98 - 17.40
Beta	0.69
RSI	48.42
Earnings Date	Mar 26, 2026

About ViroGates

ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital clinics to guide and inform individuals of their health state, and in hospitals to support clinical decisions and identify high-risk patients, as well as used for a range of acute and chronic health issues, such as cardiovascular disease, type 2 diabetes, and cancer. The company’s product includes suPARnostic TurbiLatex, a latex particle-enhan...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: VIRO

Financial Performance

In 2025, ViroGates's revenue was 8.90 million, an increase of 24.67% compared to the previous year's 7.14 million. Losses were -10.40 million, -27.52% less than in 2024.